Preparation and Characterization of Chitosan Nanoparticles for Zidovudine Nasal Delivery.

Zidovudine (AZT) is the antiretroviral drug most frequently used for the treatment of Acquired Immunodeficiency Syndrome. Its low oral bioavailability demands the development of innovative strategies to overcome the first pass metabolism. The nasal route is an option for enhanced therapeutic efficacy and to reduce the extent of the first-pass effect.

Rheological, mechanical and adhesive properties of surfactant-containing systems designed as a potential platform for topical drug delivery.

In the last few decades, nanotechnology has led to an advance in the development of topical drug delivery. Nanostructured drug delivery systems enable the compartmentalization of drugs in restricted environments, modifying the release profile and maintaining the required drug concentration for prolonged periods at the site of action and/or absorption. The development of nanostructured systems containing surfactants has evolved rapidly.